Welcome to our dedicated page for Lilly Eli & Co SEC filings (Ticker: LLY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Eli Lilly and Company (NYSE: LLY) SEC filings page on Stock Titan provides direct access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. These documents help investors understand Lilly’s capital structure, governance, financing activities and material events affecting the business.
Lilly’s common stock and several series of notes are registered under Section 12(b) of the Securities Exchange Act of 1934 and listed on the New York Stock Exchange, including common stock under the symbol LLY and multiple note series with maturities ranging from 2026 to 2061. Recent Form 8-K filings disclose items such as quarterly financial results furnished under Item 2.02, other events under Item 8.01, and governance changes under Item 5.02. For example, an August 2025 Form 8-K describes an underwriting agreement for floating-rate notes due 2028 and fixed-rate notes due between 2028 and 2065, while a November 2025 Form 8-K reports the election of a new independent director to Lilly’s board.
Through this page, users can review current and historical 8-Ks, along with other core filings such as annual reports on Form 10-K and quarterly reports on Form 10-Q when available. These filings typically include details on Lilly’s therapeutic focus areas—such as cardiometabolic health, obesity, oncology, immunology and neuroscience—its risk factors, research and development programs, and financial condition.
Stock Titan enhances access to Lilly’s filings by pairing real-time EDGAR updates with AI-powered summaries. AI-generated overviews can help explain the significance of complex documents, such as new debt offerings, governance changes or major transactions, in plain language. Users can also quickly identify insider and executive-related disclosures when they appear in Forms 3, 4 or 5, and track how financing decisions, such as multi-series note issuances, fit into Lilly’s broader capital strategy.
Whether you are analyzing LLY’s latest 10-K, reviewing 10-Q trends, or examining 8-Ks related to acquisitions, collaborations and manufacturing investments, this filings hub offers a structured view of the company’s regulatory record with tools to make dense disclosures easier to interpret.
Eli Lilly & Co. executive Daniel Skovronsky reported an acquisition of company common stock through a grant or award. On 02/09/2026, he received 15,547.862 shares at a price of $1,044.67 per share, bringing his directly held stake to 160,071.725 shares, with additional indirect holdings through a trust and spouse-related entities.
Ricks David A reported acquisition or exercise transactions in this Form 4 filing.
Eli Lilly & Co President, Chair, CEO and director David A. Ricks received a grant of 38,913.584 shares of common stock on February 9, 2026 at $1,044.67 per share. Following this award, he directly held 571,715.097 common shares.
He also reported indirect holdings through several vehicles, including the David A. Ricks 2025 GRAT, the David A. Ricks 2022 GRAT, a trust, the David A. Ricks SLAT, and a 401(k) account, while disclaiming beneficial ownership except to the extent of his pecuniary interest.
Eli Lilly executive Diogo Rau reported an equity award in company stock. On 02/09/2026, the EVP & CIDO acquired 4,432.32 shares of Eli Lilly common stock through a grant or award at a price of $1,044.67 per share. Following this transaction, Rau directly beneficially owned 26,229.69 shares of Eli Lilly common stock.
Montarce Lucas reported acquisition or exercise transactions in this Form 4 filing.
Eli Lilly & Co. executive vice president and chief financial officer Lucas Montarce reported receiving a stock award of 1,365.47 shares of common stock on February 9, 2026. The award was recorded at a price of $1,044.67 per share, bringing his directly held stake to 16,050.206 shares.
Eli Lilly executive Patrik Jonsson, EVP & President, LLY International, reported an acquisition of company stock through an equity award. On 02/09/2026 he received 4,818.052 shares of common stock at $1,044.67 per share, bringing his directly held stake to 60,646.62 shares, with additional indirect holdings in a 401(k) plan.
Eli Lilly executive Edgardo Hernandez reported an equity award of company stock. On 02/09/2026, he acquired 4,383.734 shares of Eli Lilly common stock in a grant or award at $1,044.67 per share. Following this award, he directly holds 46,095.717 shares and indirectly holds 871.35 shares through a 401(k) plan.
Eli Lilly and Company executive Anat Hakim, EVP, GC & Secretary, reported an acquisition of common stock through a grant or award. On 02/09/2026, she acquired 8,277.919 shares of Eli Lilly common stock at $1,044.67 per share, bringing her directly held stake to 22,987.024 shares.
The filing also notes indirect holdings of 15,700 shares held by the Anat Hakim SLAT and 16,875 shares held by her spouse, with a disclaimer that she disclaims beneficial ownership of these securities except to the extent of her pecuniary interest.
Eli Lilly & Co
Eli Lilly executive Kenneth L. Custer reported an equity award of company stock. On 02/09/2026, he acquired 659.28 shares of Eli Lilly common stock as a grant or award at a value of $1,044.67 per share. Following this non‑open‑market acquisition, he directly holds 10,024.855 Eli Lilly shares.
Eli Lilly and Company executive Adrienne S. Brown reported an acquisition of company stock. On February 9, 2026, the EVP, President LLY Imm received a grant or award of 1,196.308 shares of Eli Lilly common stock at $1,044.67 per share. Following this award, Brown directly beneficially owned 4,921.308 shares of Eli Lilly common stock.